
@article{ WOS:000800565100002,
Author = {Kawoosa, Fizalah and Shah, Zafar A. and Masoodi, Shariq R. and Amin,
   Asif and Rasool, Roohi and Fazili, Khalid M. and Dar, Abid Hamid and
   Lone, Asif and ul Bashir, Samir},
Title = {Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating
   the response to metformin in patients with type 2 diabetes},
Journal = {BMC ENDOCRINE DISORDERS},
Year = {2022},
Volume = {22},
Number = {1},
Month = {MAY 26},
Abstract = {Background Organic cation transporter 1 primarily governs the action of
   metformin in the liver. There are considerable inter-individual
   variations in metformin response. In light of this, it is crucial to
   obtain a greater understanding of the influence of OCT1 expression or
   polymorphism in the context of variable responses elicited by metformin
   treatment. Results We observed that the variable response to metformin
   in the responders and non-responders is independent of isoform variation
   and mRNA expression of OCT-1. We also observed an insignificant
   difference in the serum metformin levels of the patient groups. Further,
   molecular docking provided us with an insight into the hotspot regions
   of OCT-1 for metformin binding. Genotyping of these regions revealed
   SNPs 156T>C and 1222A>G in both the groups, while as 181C>T and 1201G>A
   were found only in non-responders. The 181T>C and 1222A>G changes were
   further found to alter OCT-1 structure in silico and affect metformin
   transport in vitro which was illustrated by their effect on the
   activation of AMPK, the marker for metformin activity. Conclusion Taken
   together, our results corroborate the role of OCT-1 in the transport of
   metformin and also point at OCT1 genetic variations possibly affecting
   the transport of metformin into the cells and hence its subsequent
   action in responders and non-responders.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Shah, ZA (Corresponding Author), Sherikashmir Inst Med Sci, Dept Immunol \& Mol Med, Srinagar 190011, Jammu \& Kashmir, India.
   Kawoosa, Fizalah; Shah, Zafar A.; Rasool, Roohi, Sherikashmir Inst Med Sci, Dept Immunol \& Mol Med, Srinagar 190011, Jammu \& Kashmir, India.
   Masoodi, Shariq R., Sherikashmir Inst Med Sci, Dept Endocrinol, Srinagar 190011, Jammu \& Kashmir, India.
   Amin, Asif; Fazili, Khalid M., Univ Kashmir, Dept Biotechnol, Srinagar 190006, Jammu \& Kashmir, India.
   Dar, Abid Hamid, Cent Univ Kashmir, Dept Biotechnol, Ganderbal 191201, Jammu \& Kashmir, India.
   Lone, Asif, Univ Delhi, Deshbandhu Coll, Dept Biochem, Delhi 110019, India.
   ul Bashir, Samir, Univ Northern British Columbia, Dept Chem, Prince George, BC, Canada.},
DOI = {10.1186/s12902-022-01033-3},
Article-Number = {140},
EISSN = {1472-6823},
Keywords = {Organic cation transporter 1(OCT-1; Metformin; AMPK},
Keywords-Plus = {GENETIC-VARIATION; OCT1; POLYMORPHISMS; ATM; SLC22A1; CHINESE},
Research-Areas = {Endocrinology \& Metabolism},
Web-of-Science-Categories  = {Endocrinology \& Metabolism},
Author-Email = {zafaraminshah00@gmail.com},
Affiliations = {Sher-i-Kashmir Institute of Medical Sciences; Sher-i-Kashmir Institute
   of Medical Sciences; University of Kashmir; Central University of
   Kashmir; University of Delhi; University of Northern British Columbia},
ResearcherID-Numbers = {Masoodi, Shariq/AAV-7265-2020
   Fazili, d@61/I-9758-2017
   },
ORCID-Numbers = {Lone, Asif/0000-0002-0292-240X},
Cited-References = {Bankura B, 2016, INDIA J METABOLIC SY, V5, P198, DOI 10.4172/2167-0943.1000198.
   Becker ML, 2009, PHARMACOGENOMICS J, V9, P242, DOI 10.1038/tpj.2009.15.
   Chen LG, 2010, J PHARMACOL EXP THER, V335, P42, DOI 10.1124/jpet.110.170159.
   Cook MN, 2007, DIABETIC MED, V24, P350, DOI 10.1111/j.1464-5491.2007.02078.x.
   Dujic T, 2015, DIABETES, V64, P1786, DOI 10.2337/db14-1388.
   Florez JC, 2012, DIABETES CARE, V35, P1864, DOI 10.2337/dc11-2301.
   Florez Jose C, 2011, Curr Diab Rep, V11, P467, DOI 10.1007/s11892-011-0220-0.
   Hayer M, 1999, ANN HUM GENET, V63, P473, DOI 10.1046/j.1469-1809.2000.6430267.x.
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P435, DOI 10.1021/ct700301q.
   Hirst JA, 2012, DIABETES CARE, V35, P446, DOI 10.2337/dc11-1465.
   Kanto K, 2018, J DIABETES INVEST, V9, P587, DOI 10.1111/jdi.12755.
   Kerb R, 2002, PHARMACOGENETICS, V12, P591, DOI 10.1097/00008571-200211000-00002.
   Li QC, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/3402808.
   Mahrooz A, 2015, CLIN EXP MED, V15, P159, DOI 10.1007/s10238-014-0283-8.
   Nies AT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022163.
   Nies AT, 2009, HEPATOLOGY, V50, P1227, DOI 10.1002/hep.23103.
   Riedmaier AE, 2013, TRENDS PHARMACOL SCI, V34, P126, DOI 10.1016/j.tips.2012.11.005.
   Seitz T, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0172-0.
   Sherifali D, 2010, DIABETES CARE, V33, P1859, DOI 10.2337/dc09-1727.
   Shikata E, 2007, J HUM GENET, V52, P117, DOI 10.1007/s10038-006-0087-0.
   Shokri F, 2016, INT J MOL CELL MED, V5, P1.
   Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558.
   Sur D, 2015, J Mol Genet Med, V9, P102, DOI {[}10.4172/1747-0862.C1.010, DOI 10.4172/1747-0862.C1.010].
   van Leeuwen N, 2013, CLIN PHARMACOKINET, V52, P833, DOI 10.1007/s40262-013-0076-3.
   van Leeuwen N, 2012, DIABETOLOGIA, V55, P1971, DOI 10.1007/s00125-012-2537-x.
   Zhou KX, 2011, NAT GENET, V43, P117, DOI 10.1038/ng.735.
   Zhou Y, 2015, INT J CLIN EXP PATHO, V8, P9533.},
Number-of-Cited-References = {27},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {BMC Endocr. Disord.},
Doc-Delivery-Number = {1N3NE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000800565100002},
OA = {Green Published, gold},
DA = {2024-09-07},
}
